Pharmacy Friends

Prime Therapeutics

Pharmacy Friends is a podcast dedicated to bringing industry experts to the same table to talk about what is happening in pharmacy today, what is coming in the future, and most importantly, what it means to you.

  1. JAN 22

    Reimagining the Pipeline: Cell & Gene Therapy Decisions That Shape Care

    During this episode of Pharmacy Friends you’ll hear about the rapidly evolving world of cell and gene therapy, highlighting its promise, complexity, and growing impact across the health care ecosystem. Learn about the foundational definitions, emerging clinical innovations, and the expanding pipeline of therapies expected to reach the market in the coming years. It also examines regulatory developments, forecasting approaches, financial considerations, and the human elements that shape patient and provider decision‑making. Through expert insights and real‑world examples, the conversation illustrates how Prime is helping stakeholders navigate this dynamic landscape while preparing for the transformative potential of next‑generation therapies. Listen to the latest episode of the “Pharmacy Friends” podcast Read the latest Cell & Gene Pipeline Outlook Learn more about how Prime manages cell and gene therapies In this episode: 03:46 What is Cell & Gene Therapy? 04:34 What is the Cell & Gene Therapy Pipeline? 08:13 Why pay attention to cell & gene therapies? 12:45: Collaboration with all stakeholders is important to get the right therapies to patients 20:35: Digging in new therapies that are on the horizon 22:56: Importance of the FDA commissioner's national priority voucher 25:52: What to consider when these therapies are an option 28:40: Is cost a barrier to these therapies? 31:41: 2026 cell and gene therapy outlook 36:18: Closing - books and fishing

    40 min
  2. 10/29/2025

    Real-world evidence and innovation in managed care pharmacy: Insights from AMCP Nexus 2025

    Research is more than just finding interesting stats. It's about finding better ways to deliver savings, simplicity, and support. In this episode, you’ll hear from managed care pharmacy researchers who are doing just that, delivering data driven insights to drive affordability and access in health care.    Pat Gleason, PharmD, BCPS, FCCP, FAMCP, assistant vice president of health outcomes; Nick Friedlander, PharmD, clinical program pharmacist; and Simone Ndujiuba, PharmD, BCOP, clinical oncology pharmacist senior principal; and host Alex Cook, senior public relations manager, discuss how Prime’s research helps address affordability and accessibility issues and guides health care providers and peers toward clarity on treatment for complex health conditions.  Research topics covered: Three-Year Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists Among Commercially Insured Adults with Obesity without Diabetes Trends in Real-World Persistence to Weight Loss Glucagon-Like Peptide-1 Receptor Agonists from 2021 to 2024 Among Commercially Insured Adults without Diabetes — This study earned a platinum award from AMCP.  Impact of a Medical Claims Automated Glucagon Like Peptide-1 Drugs Prior Authorization Program— This study earned a gold award from AMCP.Validation of Long-term Savings from a Pharmacist-to-Prescriber Telephonic Intervention — This study earned a gold award from AMCP. Total Cost of Care and Adverse Effects Assessment of Bispecific T-cell Engagers and Chimeric Antigen Receptor T-cell Therapies for Relapsed Refractory Follicular Lymphoma   ------------------------- Content in this podcast is for informational or educational purposes only. The content also does not substitute professional medical advice or consultations with health care professionals. Always seek advice from a physician or other health care providers with any questions you have regarding a medical treatment or condition before undertaking a new health care regimen.

    40 min
  3. A New Era in Liver Health: GLP-1s and the MASH Breakthrough

    08/21/2025

    A New Era in Liver Health: GLP-1s and the MASH Breakthrough

    In this episode, our host Maryam Tabatabai is joined by three guests Olivia Pane, PharmD; Dr. Edmundo Rodriguez Frias; and Katie Lockhart, who unpack insights from Prime Therapeutics’ latest clinical report that dives into the latest evidence-based clinical insights related to the rising prevalence and significant health impact of metabolic dysfunction-associated steatohepatitis, or MASH. MASH is a silent but serious liver condition affecting over 22 million Americans, with numbers projected to rise sharply by 2030. Listeners learn about the latest major development in liver health treatment: the FDA approval of Novo Nordisk’s semaglutide – Wegovy -- as the first GLP-1 drug indicated for MASH. We explore how this development may revolutionize care and could offer a more affordable alternative to treating this condition. The Evolution of GLP-1s www.primetherapeutics.com All Pharmacy Friends episodes Metabolic dysfunction-associated steatohepatitis (MASH) – A new era in liver health The views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice

    12 min
5
out of 5
12 Ratings

About

Pharmacy Friends is a podcast dedicated to bringing industry experts to the same table to talk about what is happening in pharmacy today, what is coming in the future, and most importantly, what it means to you.